• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TRIMETREXATE Drug Record

  • Summary
  • Interactions
  • Claims
  • TRIMETREXATE chembl:CHEMBL119 ApprovedAntineoplastic

    Alternate Names:

    TRIMETREXATE
    CI-898
    NEUTREXIN
    TRIMETREXATE GLUCURONATE
    TRIMETREXATUM
    TRIMETREXATO
    NEUTREXIN®
    chemidplus:52128-35-5
    pubchem.compound:5583
    drugbank:01157
    rxcui:42333
    chembl:CHEMBL119

    Drug Info:

    Drug Class antineoplastic agents
    Year of Approval 1993
    FDA Approval 1993
    Drug Class small molecule
    Drug Indications Antineoplastic Agents
    (2 More Sources)

    Publications:

    Miyachi et al., 1999, Microsatellite instability and clonal heterogeneity of MDR1 messenger RNA expression in trimetrexate-resistant human leukemia MOLT-3 cells developed in thymidine., Int. J. Cancer
    Polshakov et al., 1999, Structure and dynamics in solution of the complex of Lactobacillus casei dihydrofolate reductase with the new lipophilic antifolate drug trimetrexate., Protein Sci.
    Warlick et al., 2002, In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model., J. Pharmacol. Exp. Ther.
    Bertino et al., 1999, Use of variants of dihydrofolate reductase in gene transfer to produce resistance to methotrexate and trimetrexate., Prog Exp Tumor Res
    Graffner-Nordberg et al., 2001, Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii., J. Med. Chem.
    Zhu et al., Severe folate restriction results in depletion of and alteration in the composition of the intracellular folate pool, moderate sensitization to methotrexate and trimetrexate, upregulation of endogenous DHFR activity, and overexpression of metallothionein II and folate receptor alpha that, upon folate repletion, confer drug resistance to CHL cells., J. Exp. Ther. Oncol.
    Sweeney et al., 2003, Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase., Cancer Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Sowers R et al., 2011, Impairment of methotrexate transport is common in osteosarcoma tumor samples., Sarcoma
  • TRIMETREXATE   DHFR

    Interaction Score: 4.58

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    10091649 11752096 10386066 11448221 12416030 12649191 11752352 21234348


    Sources:
    TdgClinicalTrial TEND

  • TRIMETREXATE   PDF

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TRIMETREXATE   MEN1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIMETREXATE   KMT2A

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIMETREXATE   BLM

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIMETREXATE   ABCB1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10360822


    Sources:
    NCI

  • TRIMETREXATE   MAPT

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIMETREXATE   VDR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TRIMETREXATE   EHMT2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: TRIMETREXATE

    • Version: 01-August-2011

    Alternate Names:
    TRIMETREXATE Primary Drug Name

    Drug Info:
    Year of Approval 1993
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: TRIMETREXATE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antineoplastic Agents
    Drug Class small molecule
    FDA Approval 1993

    Publications:

  • NCI: TRIMETREXATE

    • Version: 14-September-2017

    Alternate Names:
    C1314 NCI drug code

    Drug Info:

    Publications:
    Miyachi et al., 1999, Microsatellite instability and clonal heterogeneity of MDR1 messenger RNA expression in trimetrexate-resistant human leukemia MOLT-3 cells developed in thymidine., Int. J. Cancer

  • DTC: TRIMETREXATE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL119 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Trimetrexate

    • Version: 2020.06.01

    Alternate Names:
    D0Y7TS TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL119

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21